Researchers from all over the world have been working tirelessly to combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 pandemic since the World Health Organization (WHO) proclaimed it to be a pandemic in 2019. Expanding testing capacities, creating efficient medications, and creating safe and efficient COVID-19 (SARS CoV-2) vaccinations that provide the human body with long-lasting protection are a few tactics that need to be investigated. In clinical studies, drug delivery techniques, including nanoparticles, have been used since the early 1990s. Since then, as technology has advanced and the need for improved medication delivery has increased, the field of nanomedicine has recently seen significant development. PNPs, or polymeric nanoparticles, are solid particles or particulate dispersions that range in size from 10 to 1000 nm, and their ability to efficiently deliver therapeutics to specific targets makes them ideal drug carriers. This review article discusses the many polymeric nanoparticle (PNP) platforms developed to counteract the recent COVID-19 pandemic-related severe acute respiratory syndrome coronavirus (SARS-CoV-2). The primary subjects of this article are the size, shape, cytotoxicity, and release mechanism of each nanoparticle. The two kinds of preparation methods in the synthesis of polymeric nanoparticles have been discussed: the first group uses premade polymers, while the other group depends on the direct polymerization of monomers. A few of the PNPs that have been utilized to combat previous viral outbreaks against SARS-CoV-2 are also covered.

Cancer is the 3rd leading cause of death globally, and the countries with low-to-middle income account for most cancer cases. The current diagnostic tools, including imaging, molecular detection, and immune histochemistry (IHC), have intrinsic limitations, such as poor accuracy. However, researchers have been working to improve anti-cancer treatment using different drug delivery systems (DDS) to target tumor cells more precisely. Current advances, however, are enough to meet the growing call for more efficient drug delivery systems, but the adverse effects of these systems are a major problem. Nanorobots are typically controlled devices made up of nanometric component assemblies that can interact with and even diffuse the cellular membrane due to their small size, offering a direct channel to the cellular level. The nanorobots improve treatment efficiency by performing advanced biomedical therapies using minimally invasive operations. Chemotherapy’s harsh side effects and untargeted drug distribution necessitate new cancer treatment trials. The nanorobots are currently designed to recognize 12 different types of cancer cells. Nanorobots are an emerging field of nanotechnology with nanoscale dimensions and are predictable to work at an atomic, molecular, and cellular level. Nanorobots to date are under the line of investigation, but some primary molecular models of these medically programmable machines have been tested. This review on nanorobots presents the various aspects allied, i.e., introduction, history, ideal characteristics, approaches in nanorobots, basis for the development, tool kit recognition and retrieval from the body, and application considering diagnosis and treatment.

Subcutaneous (SC) drug delivery is one of the best routes of drug administration to patients over intravenous (IV) administration due to the ease of application and patient acceptance. The main limitation of using the SC route is administering larger volumes of drug, greater than 3–5 mL for therapeutic dosages. Wearable injectors on body devices are an attractive option for larger-volume drug delivery to patients. Thus, the need for a self-administration strategy at home is growing faster and is required for the next level of time-dependent and high-volume drug delivery. The advances in low-cost, connected on-body delivery systems hold great opportunity for novel ways of delivering home-based drug therapy in the future.